GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sigma Healthcare Ltd (OTCPK:SIGGF) » Definitions » ROE %

Sigma Healthcare (Sigma Healthcare) ROE % : -1.97% (As of Jan. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sigma Healthcare ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Sigma Healthcare's annualized net income for the quarter that ended in Jan. 2024 was $-9 Mil. Sigma Healthcare's average Total Stockholders Equity over the quarter that ended in Jan. 2024 was $452 Mil. Therefore, Sigma Healthcare's annualized ROE % for the quarter that ended in Jan. 2024 was -1.97%.

The historical rank and industry rank for Sigma Healthcare's ROE % or its related term are showing as below:

SIGGF' s ROE % Range Over the Past 10 Years
Min: -2.49   Med: 8.05   Max: 11.83
Current: 0.74

During the past 13 years, Sigma Healthcare's highest ROE % was 11.83%. The lowest was -2.49%. And the median was 8.05%.

SIGGF's ROE % is ranked worse than
76.84% of 95 companies
in the Medical Distribution industry
Industry Median: 7.24 vs SIGGF: 0.74

Sigma Healthcare ROE % Historical Data

The historical data trend for Sigma Healthcare's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigma Healthcare ROE % Chart

Sigma Healthcare Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.44 12.50 -1.36 0.37 0.66

Sigma Healthcare Semi-Annual Data
Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.36 -0.60 1.40 4.61 -1.97

Competitive Comparison of Sigma Healthcare's ROE %

For the Medical Distribution subindustry, Sigma Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sigma Healthcare's ROE % Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sigma Healthcare's ROE % distribution charts can be found below:

* The bar in red indicates where Sigma Healthcare's ROE % falls into.



Sigma Healthcare ROE % Calculation

Sigma Healthcare's annualized ROE % for the fiscal year that ended in Jan. 2024 is calculated as

ROE %=Net Income (A: Jan. 2024 )/( (Total Stockholders Equity (A: Jan. 2023 )+Total Stockholders Equity (A: Jan. 2024 ))/ count )
=2.992/( (330.958+577.817)/ 2 )
=2.992/454.3875
=0.66 %

Sigma Healthcare's annualized ROE % for the quarter that ended in Jan. 2024 is calculated as

ROE %=Net Income (Q: Jan. 2024 )/( (Total Stockholders Equity (Q: Jul. 2023 )+Total Stockholders Equity (Q: Jan. 2024 ))/ count )
=-8.918/( (326.297+577.817)/ 2 )
=-8.918/452.057
=-1.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jan. 2024) net income data. ROE % is displayed in the 30-year financial page.


Sigma Healthcare  (OTCPK:SIGGF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=-8.918/452.057
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-8.918 / 2248.168)*(2248.168 / 825.6575)*(825.6575 / 452.057)
=Net Margin %*Asset Turnover*Equity Multiplier
=-0.4 %*2.7229*1.8264
=ROA %*Equity Multiplier
=-1.09 %*1.8264
=-1.97 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=-8.918/452.057
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-8.918 / -7.214) * (-7.214 / 17.062) * (17.062 / 2248.168) * (2248.168 / 825.6575) * (825.6575 / 452.057)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.2362 * -0.4228 * 0.76 % * 2.7229 * 1.8264
=-1.97 %

Note: The net income data used here is two times the semi-annual (Jan. 2024) net income data. The Revenue data used here is two times the semi-annual (Jan. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Sigma Healthcare ROE % Related Terms

Thank you for viewing the detailed overview of Sigma Healthcare's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sigma Healthcare (Sigma Healthcare) Business Description

Traded in Other Exchanges
Address
2125 Dandenong Road, Level 6, Clayton, Melbourne, VIC, AUS, 3168
Sigma Healthcare is an Australian pharmaceutical distributor, wholesaler and pharmacy franchisor. The revenue growth prospects and returns of pharmaceutical distribution are subdued due to ongoing Pharmaceutical Benefits Scheme, or PBS, price reform, and regulated wholesale gross margins being capped at 7% for community pharmacy. As a result, Sigma and its competitors are seeking to expand into unregulated revenue streams. In addition, pharmacy ownership is restricted to pharmacists, thereby excluding direct corporate ownership and requiring exposure via a franchise business model.